Influenza and Other Respiratory Viruses

Papers
(The H4-Index of Influenza and Other Respiratory Viruses is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
339
82
Effectiveness of XBB.1.5 Monovalent COVID‐19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS‐EHR Network Study74
Cross‐Reactive Antibody Responses to Coronaviruses Elicited by SARS‐CoV‐2 Infection or Vaccination71
Issue Information51
Issue Information47
Comparative complete scheme and booster effectiveness of COVID‐19 vaccines in preventing SARS‐CoV‐2 infections with SARS‐CoV‐2 Omicron (BA.1) and Delta (B.1.617.2) variants: A case–case study based on45
A novel household‐based patient outreach pilot program to boost late‐season influenza vaccination rates during the COVID‐19 pandemic43
Meeting Report: Controlled Human Influenza Virus Infection Model Studies: Current Status and Future Directions for Innovation42
COVID‐19 Vaccine Effectiveness Against Hospitalization in Older Adults, VEBIS Hospital Network, Europe, September 2024–May 202538
Next‐Generation Sequencing for Characterizing Respiratory Tract Virome and Improving Detection of Viral Pathogens in Children With Pneumonia37
Effectiveness of the XBB.1.5 COVID‐19 Vaccines Against SARS‐CoV‐2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 t36
Infection‐induced seroconversion and seroprevalence of SARS‐CoV‐2 among a cohort of children and youth in Montreal, Canada36
Cost‐Effectiveness Analysis of a Maternal Vaccination Program Against Respiratory Syncytial Virus in Norway33
SARS‐CoV‐2 infection rate in Antananarivo frontline health care workers, Madagascar29
A comparative immune response to COVID‐19 vaccination between children and adults28
Antibody titres elicited by the 2018 seasonal inactivated influenza vaccine decline by 3 months post‐vaccination but persist for at least 6 months27
EMARIS Conference 2023: Convergence of science, policy, and practice on acute respiratory infections in post COVID‐19 Eastern Mediterranean Region27
Low prevalence of seasonal influenza viruses in Hong Kong, 202227
No evidence for HPAI H5N1 2.3.4.4b incursion into Australia in 202227
Antigenic Characterization of H1N1 Influenza Viruses That Circulated During the 2019–2020 Season in Philadelphia, Pennsylvania26
Evaluating Bacillus Calmette–Guérin Polysaccharide Nucleic Acid as an Adjuvant for Influenza Vaccines in Mice26
Avian Influenza Virus (H5N1) Was Not Detected Among Dairy Cattle and Farm Workers in Pakistan26
Antibiotic prescription for outpatients with influenza and subsequent hospitalisation: A cohort study using insurance data26
Comparative Effectiveness of Baloxavir Marboxil and Oseltamivir Treatment in Reducing Household Transmission of Influenza: A Post Hoc Analysis of the BLOCKSTONE Trial26
Issue Information25
1.5603578090668